GW4869 (2.5 μg/g, i.p.) causes inhibition of exosome release blocks LPS-stimulated pro-inflammatory cytokine production and cardiac inflammation in mice. GW4869 mitigates LPS-caused myocardial dysfunction and improves survival in mice[2].
GW4869 (2.5 μg/g, i.p.) blocks the production of pro-inflammatory cytokines and cardiac inflammation in CLP mice[2].
| Animal Model: | 10-12 weeks old Male wild-type C57BL/6 mice (Endotoxin-Challenged Mice)[2]. |
| Dosage: | 2.5 μg/g. |
| Administration: | I.P. once (1 h later, followed by an i.p. injection of LPS (2.5 μg/g, 100 μL)). |
| Result: | Significantly decreased exosome levels by 37% in sera, compared to levels collected from control mice. At 12 h after LPS injection, the levels of circulating exosomes
were increased significantly compared to PBS-controls, as evidenced by a 1.7-fold elevation in the AChE activity.
|
| Animal Model: | 10-12 weeks old Male wild-type C57BL/6 mice (CLP Polymicrobial Sepsis Model)[2]. |
| Dosage: | 2.5 μg/g. |
| Administration: | I.P. once (before sham or CLP surgery). |
| Result: | Decreased exosome concentration by 33% compared to mice injected with PBS in sham-surgery controls.
CLP-stimulated exosome release was significantly inhibited by pre-treatment of CLP mice compared to CLP mice pre-treated with PBS.
|
